Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is in a strong position to continue its positive gross margin trend, with 67% projected for FY26. The company's proprietary clinical treatments and collaboration with SoundHealth set it apart from traditional oral appliance options as a more effective, less invasive, and more durable therapy for sleep-disordered breathing. As the company continues to open new affiliated sleep centers and focus on its core business model, there may be some risks associated with balance sheet and liquidity, but the potential for success in the sleep center opportunity outweighs these concerns and affirms our positive outlook for the company's stock.

Vivos Therapeutics is facing numerous challenges, including a significant rise in expenses due to the consolidation of operations at SCN and uncertainty surrounding their revenue ramp. These risks have led to a negative outlook on their stock, with analysts revising estimates for the company's EPS and lowering their price target to $3. The potential rewards from the company's market potential and favorable product positioning may provide some upside but are offset by risks such as low visibility on revenues and margins and potential dilution from financing. The company's valuation was determined using a comparable universe analysis and an EV/Revenue multiple of 3.0x, resulting in a projected share price of approximately $2.50. However, risks to achieving this price target include potential competition, regulatory concerns, and the company's ability to secure capital and expand operations. As a result, the current negative outlook on Vivos Therapeutics's stock reflects the uncertainty and risks surrounding its growth and profitability.